Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen-Based Risk Assessment in Younger Men. Eur Urol 2012;61:8-9

摘要

We appreciate the commentary from Strope and Andriole. We agree with their points about potential overdiagno-sis with widespread prostate-specific antigen (PSA)-based testing of men in their 40s as well as about the need for well-defined follow-up protocols for those found to be at high risk. Nevertheless, overdiagnosis rates calculated in older men should not be extrapolated to younger men. In the European Randomized Study of Screening for Prostate Cancer (ERSPC), for example, overdiagnosis was estimated at 56% at age 75 versus 27% at age 55. Moreover, even low-risk disease in healthy young men may cause morbidity or mortality in the distant future.